Skip to content

Study · Randomized controlled trial · 2020

3 results

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.

Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Pratley RE, Linder M, Monk Fries T, Ørsted DD, Zinman B

Diabetes care4 May 2020Cited by 135 (Europe PMC)

PMID32366578 (opens in a new tab)PMCIDPMC7305014 (opens in a new tab)DOI10.2337/dc19-2251 (opens in a new tab)PepBankPUB-32366578
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes in LEADER, HbA1c was a potential mediator of the effect of liraglutide on major adverse cardiovascular events.

    In plain wordsIn adults with type 2 diabetes, HbA1c may explain part of how liraglutide lowered heart events compared with placebo.

    Peptide
    Liraglutide
    Outcome
    Not applicableMediation of liraglutide effect on MACE by HbA1c
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation by HbA1c (Cox method)
    ≤ 41%
    MACE
    Mediation by HbA1c (Vansteelandt method)
    ≤ 83%
    MACE

    Source sentences

    Summary
    Analyses using the Cox methods and Vansteelandt method indicated potential mediation by HbA1c (up to 41% and 83% mediation, respectively)
    1 context sentence
    Summary · context
    The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist l…
  2. 02HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes in LEADER, urinary albumin-to-creatinine ratio was a potential mediator of the effect of liraglutide on major adverse cardiovascular events.

    In plain wordsIn adults with type 2 diabetes, urine albumin levels may explain a smaller part of how liraglutide lowered heart events compared with placebo.

    Peptide
    Liraglutide
    Outcome
    Not applicableMediation of liraglutide effect on MACE by UACR
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation by UACR (Cox method)
    ≤ 29%
    MACE
    Mediation by UACR (Vansteelandt method)
    ≤ 33%
    MACE

    Source sentences

    Summary
    UACR (up to 29% and 33% mediation, respectively)
    1 context sentence
    Summary · context
    The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist l…
  3. 03HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes in LEADER, mediation effects of the other candidate mediators on the liraglutide effect on MACE were small.

    In plain wordsIn adults with type 2 diabetes, other factors such as body weight explained little of how liraglutide lowered heart events compared with placebo.

    Peptide
    Liraglutide
    Outcome
    Not applicableMediation of liraglutide effect on MACE by other candidates
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mediation effects were small for other candidates.
    1 context sentence
    Summary · context
    The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist l…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.